Two Cases of Amivantamab-Induced Pneumonitis in Patients With NSCLC: Case Report

Although drug-induced interstitial lung disease has been reported with cancer-directed antibody-drug conjugates and EGFR tyrosine kinase inhibitors, it remains a rare event in patients treated with amivantamab. In this report, we present two cases of suspected amivantamab-related drug-induced inters...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Alexander J. DeWeerd, MD, Elizabeth Sun, BS, Wade T. Iams, MD, MSCI
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Subjects:	Amivantamab Non–small cell lung cancer Canonical EGFR mutations Interstitial lung disease Case report
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364325000219